Improved survival in multiple myeloma and the impact of novel therapies
Top Cited Papers
Open Access
- 1 March 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (5), 2516-2520
- https://doi.org/10.1182/blood-2007-10-116129
Abstract
Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy hKeywords
This publication has 35 references indexed in Scilit:
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple MyelomaMayo Clinic Proceedings, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958